These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19733721)

  • 1. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.
    White WB; Schnitzer TJ; Fleming R; Duquesroix B; Beekman M
    Am J Cardiol; 2009 Sep; 104(6):840-5. PubMed ID: 19733721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of naproxcinod on blood pressure in patients with osteoarthritis.
    White WB; Schnitzer TJ; Bakris GL; Frayssinet H; Duquesroix B; Weber M
    Am J Cardiol; 2011 May; 107(9):1338-45. PubMed ID: 21371681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.
    Karlsson J; Pivodic A; Aguirre D; Schnitzer TJ
    J Rheumatol; 2009 Jun; 36(6):1290-7. PubMed ID: 19411388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study.
    Schnitzer TJ; Kivitz A; Frayssinet H; Duquesroix B
    Osteoarthritis Cartilage; 2010 May; 18(5):629-39. PubMed ID: 20202489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study.
    Baerwald C; Verdecchia P; Duquesroix B; Frayssinet H; Ferreira T
    Arthritis Rheum; 2010 Dec; 62(12):3635-44. PubMed ID: 20722026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure effects of naproxcinod in hypertensive patients.
    Townsend R; Bittar N; Rosen J; Smith W; Ramsay A; Chrysant SG; Weiss R; Pivodic A; Duquesroix B; Djian J
    J Clin Hypertens (Greenwich); 2011 May; 13(5):376-84. PubMed ID: 21545399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.
    Houston MC; Weir M; Gray J; Ginsberg D; Szeto C; Kaihlenen PM; Sugimoto D; Runde M; Lefkowitz M
    Arch Intern Med; 1995 May; 155(10):1049-54. PubMed ID: 7748048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
    Lohmander LS; McKeith D; Svensson O; Malmenäs M; Bolin L; Kalla A; Genti G; Szechinski J; Ramos-Remus C;
    Ann Rheum Dis; 2005 Mar; 64(3):449-56. PubMed ID: 15345500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis.
    Wallace JL; Viappiani S; Bolla M
    Trends Pharmacol Sci; 2009 Mar; 30(3):112-7. PubMed ID: 19230986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen, NO-naproxen.
    Drugs R D; 2007; 8(4):255-8. PubMed ID: 17596112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A
    Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis.
    Derici U; Goker B; Ayerden-Ebinc F; Altok KR; Erten Y; Haznedaroglu S; Aydin M; Arinsoy T; Sindel S
    Int J Tissue React; 2005; 27(2):69-73. PubMed ID: 16035651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study.
    Schnitzer TJ; Hochberg MC; Marrero CE; Duquesroix B; Frayssinet H; Beekman M
    Semin Arthritis Rheum; 2011 Feb; 40(4):285-97. PubMed ID: 20828790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1β.
    Cheleschi S; Pascarelli NA; Valacchi G; Di Capua A; Biava M; Belmonte G; Giordani A; Sticozzi C; Anzini M; Fioravanti A
    Int Immunopharmacol; 2015 Sep; 28(1):794-801. PubMed ID: 26292179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.
    Gualtierotti R; Zoppi A; Mugellini A; Derosa G; D'Angelo A; Fogari R
    Expert Opin Pharmacother; 2013 Oct; 14(14):1875-84. PubMed ID: 23883161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.